Development of Novel Anti-Inflammatory Agents

对安全有效的抗炎药的需求尚未得到满足。由于P38MAPK细胞内信号调节多种促炎细胞因子的作用，它似乎是一个理想的候选途径。P38抑制剂因其在肝细胞内的毒性而受到限制。因此，该计划的目的是根据已知的构效关系开发具有增强的P38 MAPK抑制作用和降低肝脏毒性的药物。

There is an unmet need for safe and effective anti-inflammatory drugs. Because P38 MAPK intracellular signalling modulates multiple pro-inflammatory cytokine actions, it appears to be an ideal candidate pathway. P38 inhibitors have been limited by their toxicity within hepatocytes. The aim of this program therefore is to develop agents with enhanced P38 MAPK inhibitory effects as well as reduced liver toxicity based on known structure activity relationships.